Navigation Links
New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes
Date:4/23/2010

e treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis.  Welchol has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones.  Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.  Welchol has not been studied in children younger than 10 years of age or in pre-menarchal girls.  Welchol is available in two formulations, Welchol tablets and Welchol® for Oral Suspension.

In clinical studies of adult patients with type 2 diabetes, Welchol lowered A1C, fasting plasma glucose and LDL-C, important risk factors for cardiovascular disease.*  In clinical studies of patients with elevated LDL-C, Welchol lowered LDL-C when used as monotherapy, when added to statin therapy, or as initial combination with statin therapy.(2)

*The effect of Welchol on cardiovascular morbidity and mortality has not been determined.

IMPORTANT INFORMATION ABOUT WELCHOL (colesevelam HCl)

Indications

Welchol is indicated as an adjunct to diet and exercise to:

  • reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenyme (HMG CoA) reductase inhibitor
  • reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia, as monotherapy or in combination with a statin after failing an adequate trial of diet therapy
  • improve glycemic control in adults with type 2 diabetes mellitus

Important Limitati
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
2. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
3. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
4. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
5. New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis
6. Tobiras Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
7. NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines
10. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
11. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... two healthcare conferences during the third quarter, the 2014 ... Global Healthcare 2014 Conference.  Alexza,s corporate presentation will be ... on each event are below: , 2014 ... in Boston , MA.  The format ...
(Date:7/29/2014)... -- Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today reported net income for the quarter ended June ... and non-GAAP net income of $94.0 million, or $0.88 per ... earlier was $93.3 million, or $0.81 per diluted share, and ... share.  Net sales for the quarter ended ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... GTHR.PK), announces it will soon begin offering its Real Time,PCR ... , GeneThera is set ... January of 2009. According to GeneThera Chairman, Dr. Tony ... PCR test for Johne,s disease,called HerdGuard(TM) by the first of ...
... A new cancer treatment is,realizing outstanding results against ... large, stage 4 tumor was reduced in size ... no longer could be definitely,identified on scans. Pancreatic ... diagnosis. NeoPlas Innovation,s combination of FDA-approved drugs,appears to ...
Cached Medicine Technology:GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4New Cancer Treatment Shrinks Pancreatic Tumor 2
(Date:7/29/2014)... LEBANON, NH (July 29, 2014) Using quality improvement ... Northern New England Cardiovascular Disease Study Group, researchers have ... undergoing a procedure with contrast dye. , Currently, 7-15 ... procedure with contrast-dye end up with kidney injury, which ... function leading to temporary or permanent dialysis, says a ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a ... celebrated throughout that time by picnics, barbecues and beach ... mark the start of a period that will witness ... In 2012 nearly 1.000 people were killed in crashes ... to Labor Day. , The summer's warmer weather, longer ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 During his 37 ... Bruce, DMD & Associates, has had a steady stream of ... dentistry. These students have now gone on to dental school ... proving that the shadowing program helps college students find success. ... Bruce has given them the chance to see a realistic ...
(Date:7/29/2014)... A team of scientists, led by ... has developed a blood test for Alzheimer’s disease risk ... of Alzheimer’s disease interventions, according to an article published ... and this study represents one of several pieces that ... couple of years,” Ethell said. , The study, “Women ...
(Date:7/29/2014)... July 29, 2014 Just months after ... to 4 new states, the exciting FX family does ... and one time farmboy from Arkansas, is shocking the ... innovative event technologies to the masses. This time ... packed island of Jamaica. This new office is ...
Breaking Medicine News(10 mins):Health News:Reducing kidney injury using a quality improvement method 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Arthur Bruce Dental Helps College Students 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Atlanta Special FX Rapidly Expanding Just Opens First International Corporate Office in Jamaica 2
... to Ensure Equitable Protections,for All Americans and Their ... America,s,Health (TFAH) issued the following statement on the ... Services(HHS) Draft Guidances to Assist in,Preparation for an ... government must do all it can to ensure ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... Schroeder will present the corporate overview on,Wednesday, June ... pm Pacific Time),during the Seventh Annual Needham & ...
... DALLAS, June 4 The echocardiography lab ... by the,Inter-societal Commission for the Accreditation of ... two hospitals in the region,accredited by the ... is paramount," said Dr.,Jorge Cheirif, Presbyterian,s chief ...
... abuse after college as well as face ... College students with a "dense" family history of alcoholism ... study says. , While most university students tend to ... young adults, some develop alcohol-use disorders, or AUDs. Most ...
... participants saw urine protein levels lowered significantly , , WEDNESDAY, June ... to combat some of the damaging effects of type 2 ... a new Danish study has found. , But ... and aliskiren (Tekturna) to block the activity of a molecule ...
... progress among Hispanic children , , WEDNESDAY, June 4 (HealthDay ... to engage in risky health behaviors, including sexual intercourse, ... U.S. health officials said Wednesday. , While there have ... students, Hispanic students remain at higher risk for some ...
Cached Medicine News:Health News:Trust for America's Health on New HHS Influenza Pandemic Draft Guidance 2Health News:Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference on June 11, 2008 in New York 2Health News:Echocardiography Lab at Presbyterian Hospital of Dallas Achieves Prestigious Reaccreditation 2Health News:Family History of Alcoholism Puts Student Drinkers at Risk 2Health News:Two-Drug Combo Reduces Diabetic Kidney Damage 2Health News:Two-Drug Combo Reduces Diabetic Kidney Damage 3Health News:Fewer U.S. High School Students Engage in Risky Behaviors 2Health News:Fewer U.S. High School Students Engage in Risky Behaviors 3
... Spatula Tips That Mimic Corneal Curvature. Designed To ... Created With The IntraLase TMFS Laser System., ... Of The Forceps Are Designed To Facilitate Access ... Achieved, The Cross-Action Forceps Design Allows The Surgeon ...
... Allowing The Exact,Outer Diameter Measurement Of A ... ,Increments.,Easy And Quick To Use, With One-HandedOperation. ... Over A Cornea For Confirmation Of Exact ... ,Guaranteed For ...
... Safely And Easily Cut Foldable Lenses Through ... The Incision., ,Specially Designed To Cut And ... Lenses With Ease With One Instrument., ,Ideal ... Lenses Which Are Damaged, The Wrong Diopter ...
... Gauge Measures 360 Degrees & Can Be ... A Cornea. 7mm Inner Diameter & 14mm Outer ... Only Astigmatism Gauge That Can Be Set For ... Degree Around The Globe., ,Marks Single Or Paired ...
Medicine Products: